Thymic carcinoma: Current and future therapeutic interventions

Expert Opinion on Investigational Drugs

Volumn 19, Issue 8, 2010, Pages 1007-1016

  Weiss, Glen J ^a  

^a HonorHealth and the Scottsdale Lincoln Health Network   (United States)

Author keywords

Biologics; Chemotherapy; Clinical trial; Drug development; Target; Thymic carcinoma

Indexed keywords

AMRUBICIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IMATINIB; IMC A12; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; OCTREOTIDE; OSI 906; PACLITAXEL; PHA 848125AC; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE;

ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE ESCALATION; GENE OVEREXPRESSION; HUMAN; PRACTICE GUIDELINE; REVIEW; SALVAGE THERAPY; THYMECTOMY; THYMIC CARCINOMA; THYMUS CANCER; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; ANATOMY AND HISTOLOGY; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); FEMALE; GENETICS; GROWTH, DEVELOPMENT AND AGING; MALE; MULTIMODALITY CANCER THERAPY; ONCOGENE; PATHOLOGY; PATHOPHYSIOLOGY; THYMOMA; THYMUS; THYMUS NEOPLASMS;

ANTINEOPLASTIC AGENTS; BIOLOGICAL THERAPY; CISPLATIN; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; NEOPLASM STAGING; ONCOGENES; SALVAGE THERAPY; THYMOMA; THYMUS GLAND; THYMUS NEOPLASMS;

EID: 77954732531     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.504708     Document Type: Review

References (55)

1. Rosado-de-Christenson ML, Strollo DC, Marom EM. Imaging of thymic epithelial neoplasms. Hematol Oncol Clin North Am 2008;22:409-31
2. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 2003;76:878-84
3. Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 2003;105:546-51
4. Duwe BV, Sterman DH, Musani AI. Tumors of the mediastinum. Chest 2005;128:2893-909
5. Srirajaskanthan R, Toubanakis C, Dusmet M, et al. A review of thymic tumours. Lung Cancer 2008;60:4-13
6. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
7. Moran CA, Suster S. Thymic carcinoma: current concepts and histologic features. Hematol Oncol Clin North Am 2008;22:393-407
8. Suster S, Rosai J. Thymic carcinoma. A clinicopathologic study of 60 cases. Cancer 1991;67:1025-32
9. Shimosato Y, Mukai K. Tumors of the mediastinum. 1 edition. (Volume 21). American Registry of Pathology; 1997. p. 41
10. Shimosato Y, Kameya T, Nagai K, et al. Squamous cell carcinoma of the thymus. An analysis of eight cases. Am J Surg Pathol 1977;1:109-21
11. Ionescu DN, Sasatomi E, Cieply K, et al. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 2005;103:630-6
12. Suzuki E, Sasaki H, Kawano O, et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 2006;36:351-6
13. Hayashi Y, Ishii N, Obayashi C, et al. Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21. Virchows Arch 1995;426:43-50
14. Pan CC, Chen PC, Wang LS, et al. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopathology 2003;43:165-72
15. Nakagawa K, Matsuno Y, Kunitoh H, et al. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest 2005;128:140-4
16. Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 2004;202:375-81
17. Chen FF, Yan JJ, Jin YT, et al. Detection of bcl-2 and p53 in thymoma: expression of bcl-2 as a reliable marker of tumor aggressiveness. Hum Pathol 1996;27:1089-92
18. Khoury T, Arshad A, Bogner P, et al. Apoptosis-related (survivin, Bcl-2), tumor suppressor gene (p53), proliferation (Ki-67), and non-receptor tyrosine kinase (Src) markers expression and correlation with clinicopathologic variables in 60 thymic neoplasms. Chest 2009;136:220-8
19. Tateyama H, Eimoto T, Tada T, et al. p53 protein expression and p53 gene mutation in thymic epithelial tumors. An immunohistochemical and DNA sequencing study. Am J Clin Pathol 1995;104:375-81
20. Hirabayashi H, Fujii Y, Sakaguchi M, et al. p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. Int J Cancer 1997;73:639-44
21. Weirich G, Schneider P, Fellbaum C, et al. p53 alterations in thymic epithelial tumours. Virchows Arch 1997;431:17-23
22. Pich A, Chiarle R, Chiusa L, et al. p53 expression and proliferative activity predict survival in non-invasive thymomas. Int J Cancer 1996;69:180-3
23. Suzuki M, Chen H, Shigematsu H, et al. Aberrant methylation: common in thymic carcinomas, rare in thymomas. Oncol Rep 2005;14:1621-4
24. Hirose Y, et al. Aberrant methylation of tumour-related genes in thymic epithelial tumours [abstract]. Lung Cancer 2009;2:155-9
25. Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485-92
26. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and genetics of tumors of the lung, pleura, thymus and heart. In: World Health Organization Classification of Tumours. IARC Press, Lyon, France; 2004
27. . The latest NCCN consensus recommendations for treating thymic tumors.
28. Hernandez-Ilizaliturri FJ, Tan D, Cipolla D, et al. Multimodality therapy for thymic carcinoma (TCA): results of a 30-year single-institution experience. Am J Clin Oncol 2004;27:68-72
29. Magois E, Guigay J, Blancard PS, et al. Multimodal treatment of thymic carcinoma: report of nine cases [abstract]. Lung Cancer 2008;59(1):126-32
30. Huang J, Rizk N, Park B, et al. Recent clinical experience with multimodality therapy in thymic carcinoma. 2007 ASCO Annual Meeting Proceedings Part I [abstract]. J Clin Oncol 2007;25(18S):18003
31. Yano M, Sasaki H, Yokoyama T, et al. Thymic carcinoma: 30 cases at a single institution. J Thorac Oncol 2008;3:265-9
32. Loehrer PJ Sr, Jiroutek M, Aisner S, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 2001;91:2010-15
33. Lemma GL, Loehrer PJ, Lee JW, et al. A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99. J Clin Oncol 2008;26(Suppl):abstract 8018
34. Igawa S, Murakami H, Takahashi T, et al. Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma [abstract]. Lung Cancer 2010;67(2):194-7
35. Koizumi T, Takabayashi Y, Yamagishi S, et al. Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy). Am J Clin Oncol 2002;25:266-8
36. Giaccone G, Wilmink H, Paul MA, et al. Systemic treatment of malignant thymoma: a decade experience at a single institution. Am J Clin Oncol 2006;29:336-44
37. Kurup A, Burns M, Dropcho S, et al. Phase II study of gefitinib treatment in advanced thymic malignancies. 2005 ASCO Annual Meeting Proceedings Part I of II [abstract]. J Clin Oncol 2005;23(16S):7068
38. Bedano PM, Perkins S, Burns M, et al. A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 2008;26(Suppl):abstract 19087
39. Giaccone G, Smit EF, Van Groeningen C, Hogendorn P. Phase II study of imatinib in patients with WHO B3 and C thymomas. J Clin Oncol 2008;26(Suppl):abstract 14665
40. Salter JT, Lewis D, Yiannoutsos C, et al. Imatinib for the treatment of thymic carcinoma. J Clin Oncol 2008;26(Suppl):abstract 8116
41. Loehrer PJ Sr, Wang W, Johnson DH, et al. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 2004;22:293-9
42. Palmieri G, Montella L, Martignetti A, et al. Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer 2002;94:1414-20
43. Giaccone G, Rajan A, Carter C, et al. Phase II study of the histone deacetylase inhibitor belinostat in thymic malignancies. Available from: http://www.topotarget.com/multimedia/Microsoft-PowerPoint-Belinostat-poster-for- Thymoma-ASCO-2009-Final1.pdf, Accessed 15 March 2010
44. Li XF, Hen Q, Uang WX, et al. Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report [abstract]. Med Oncol 2009;26(2):157-60
45. Bisagni G, Rossi G, Cavazza A, et al. Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 2009;4:773-5
46. Loehrer PJ, Yiannoutsos CT, Dropcho S, et al. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. 2006 ASCO Annual Meeting Proceedings Part I 240 [abstract]. J Clin Oncol 2006;24(18S):7079
47. Koizumi T, Agatsuma T, Ichiyama T, et al. Salvage chemotherapy with amrubicin and platinum for relapsed thymic carcinoma: experience in six cases. Med Oncol 2010;27(2):392-6 Available from: http://www.clinicaltrials.gov, Accessed March 2010
48. Rothenberg M, Poplin E, Sandler A, et al. Phase I dose-escalation study of the anti-IGF-IR recombinant human IgG1 monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors [abstract]. AACR Meeting Abstracts 2007; p. C84
49. Lindsay CR, Chan E, Evans TR, et al. Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors. 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2009;27(15S):abstract 2559
50. Zettl A, Strobel P, Wagner K, et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 2000;157(1):257-66
51. Weide LG, Ulbright TM, Loehrer PJ Sr, et al. Thymic carcinoma. A distinct clinical entity responsive to chemotherapy. Cancer 1993;71:1219-23
52. Von Hoff DD, Korn R, Mousses S. Pancreatic cancer: could it be that simple? A different context of vulnerability. Cancer Cell 2009;16:7-8
53. Nelson KM, Weiss GJ. MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther 2008;7:3655-60
54. Kuhn E, Wistuba II. Molecular pathology of thymic epithelial neoplasms. Hematol Oncol Clin North Am 2008;22:443-55
55. Armstrong P, Wilson AG, Dee P, Hansell DM. Imaging of Diseases of the Chest. 2nd edition. St. Louis, Mosby-Year Book, 1995, London, UK; 2000. p. 789-949